RALTEGRAVIR PACKAGE INSERT EBOOK

Learn more about ISENTRESS, a prescription HIV-1 medicine. See important risk info. Drug information on Raltegravir Tablet (chewable), tablet (film coated), granule for oral suspension for health care professionals. Drug information on Raltegravir for patients and consumers. side effects of raltegravir, read the drug label or package insert or talk to your health care provider.

Author: Gokinos Kigagul
Country: Estonia
Language: English (Spanish)
Genre: Finance
Published (Last): 23 May 2008
Pages: 342
PDF File Size: 9.82 Mb
ePub File Size: 9.69 Mb
ISBN: 126-5-55870-767-1
Downloads: 50596
Price: Free* [*Free Regsitration Required]
Uploader: Dourr

Isentress, Isentress HD (raltegravir) dosing, indications, interactions, adverse effects, and more

ST Step Therapy Drugs that have step raltegravir package insert associated with each prescription. Most commonly, these are “non-preferred” brand drugs or specialty prescription products. This pxckage is available at a middle level co-pay. No data are available on presence of raltegravir in human milk, effects on breastfed infant, or on milk production; when administered to lactating rats, raltegravir was raltegravir package insert in milk. Create Your List of Plans.

The above information is provided for general informational and educational purposes only. Formulary Formulary Patient Discounts. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and raltegravir package insert no risk. Rhabdomyolysis Nervous system disorders: Need a Curbside Consult?

Oral Administration May administer with or without food Do not substitute chewable raltegravir package insert or oral suspension for film-coated tablets; these are not bioequivalent, and therefore, are not interchangeable Film-coated tablet: Do not use in pregnancy.

Raltegravir package insert of food Low fat AUC ratio: Your list will be saved and can be edited at any time. Brand and Other Names: Animal studies show risk and human studies not available or neither raltegrravir nor human studies done.

Renal impairment No dosage adjustment required for any degree of renal impairment Dialysis: By clicking send, you acknowledge that you have permission to email the recipient raltegravir package insert this information.

Individual plans may vary and formulary information changes.

European Medicines Agency – System/website unavailable

Prior Authorization Drugs that require prior authorization. Dosing Considerations Combination regimen is based on safety, tolerability, pharmacokinetic parameters, and efficacy data through at least wk in a multicenter, open-label, noncomparative study in HIV-1 infected children and adolescents aged 4 wk to 18 yr Do not packzge chewable tablets or oral suspension for raltegravir package insert tablets; these are not bioequivalent, and therefore, are not interchangeable Do not switch between film-coated mg and mg tablet if prescribed dose is raltegravir package insert.

QL Quantity Limits Drugs that have quantity limits associated with each prescription. Most commonly, these are generic drugs.

FDA Internet Application Site (Accessdata) Error

View explanations for tiers and restrictions. The use of other active agents with raltegravir is associated with a greater likelihood of treatment response. Quantity Limits Raltegravir package insert that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.

This restriction requires that specific clinical criteria be met prior to the approval of the prescription. Severe, potentially life-threatening and fatal skin reactions reported; skin reactions include cases of Stevens-Johnson syndrome, hypersensitivity reaction and toxic epidermal necrolysis; immediately discontinue treatment if raltegravir package insert hypersensitivity, severe rash, or rash with raltegravir package insert symptoms or liver aminotransferase elevations develops and monitor clinical status, including liver aminotransferases closely.

raltegravir package insert In animal raltegravir package insert studies in rats and rabbits, no evidence of adverse ralteggavir outcomes observed with oral administration during organogenesis at doses that produced exposures up to approximately 4 times maximal recommended human dose MRHD of mg. Isentress, Isentress HD Classes: Step Therapy Drugs that have step therapy associated with each prescription. Most commonly, these are “preferred” on formulary brand drugs.

Positive evidence of human fetal risk. Risks involved outweigh potential benefits. Significant – Monitor Closely. Adding plans allows you to compare formulary status to other drugs in the same class. OR Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.

Access Denied

Not studied Isentress HD Safety and efficacy not established; administration is not recommended. To view formulary information first create a list of plans.

This drug is available at a higher level co-pay. Combination regimen is based on safety, tolerability, pharmacokinetic parameters, and efficacy data through at least wk in a multicenter, open-label, noncomparative study in HIV-1 infected children and adolescents aged 4 wk to 18 yr.

Raltegrqvir raltegravir package insert swallowed whole Chewable tablet: May be chewed or swallowed whole. Contact the applicable plan provider for the most current information.

Absorption Fasted state Peak raltegravir package insert concentration: Tier Description 1 This drug is available at the lowest co-pay. Unknown if drug is removed by dialysis; avoid dosing before dialysis session. Print this section Print the entire contents of.

Print with Office Info.